Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
A partir d'échantillons de sang périphérique prélevés sur 213 patients atteints d'un cancer colorectal et sur 187 témoins, cette étude met en évidence une signature, basée sur l'expression de 18 gènes, susceptible d'être utilisée pour le diagnostic et la détection précoce de la maladie
Purpose:The early detection of colorectal cancer (CRC) is crucial for successful treatment and patient survival. However, compliance with current screening methods remains poor. This study aimed to identify an accurate blood-based gene expression signature for CRC detection.
Experimental Design:Gene expression in peripheral blood samples from 216 patients with CRC tumors and 187 controls was investigated in the study. We first performed a microarray analysis to select candidate genes that were significantly differentially expressed between cancer patients and controls. A quantitative reverse transcription polymerase chain reaction assay was then used to evaluate the expression of selected genes. A gene expression signature was identified using a training set (n = 200) and then validated using an independent test set (n = 160).
Results:We identified an 18-gene signature that discriminated the CRC patients from controls with 92% accuracy, 91% sensitivity and 92% specificity. The signature performance was further validated in the independent test set with 86% accuracy, 84% sensitivity and 88% specificity. The area under the receiver operating characteristics curve was 0.94. The signature was shown to be enriched in genes related to immune functions.
Conclusions:This study identified an 18-gene signature that accurately discriminated CRC patients from controls in peripheral blood samples. Our results prompt the further development of blood-based gene expression biomarkers for the diagnosis and early detection of CRC.
Clinical Cancer Research , résumé, 2013